PKMYT1 is a regulator of CDK1 phosphorylation and is
a compelling
therapeutic target for the treatment of certain types of DNA damage
response cancers due to its established synthetic lethal relationship
with CCNE1 amplification. To date, no selective inhibitors
have been reported for this kinase that would allow for investigation
of the pharmacological role of PKMYT1. To address this need compound 1 was identified as a weak PKMYT1 inhibitor. Introduction
of a dimethylphenol increased potency on PKMYT1. These dimethylphenol
analogs were found to exist as atropisomers that could be separated
and profiled as single enantiomers. Structure-based drug design enabled
optimization of cell-based potency. Parallel optimization of ADME
properties led to the identification of potent and selective inhibitors
of PKMYT1. RP-6306 inhibits CCNE1-amplified
tumor cell growth in several preclinical xenograft models. The first-in-class
clinical candidate RP-6306 is currently being evaluated
in Phase 1 clinical trials for treatment of various solid tumors.
PKMYT1 is an important regulator of CDK1 phosphorylation and is a compelling therapeutic target for the treatment of certain types of DNA damage response cancers due to its established synthetic lethal relationship with CCNE1 amplification. To date, no selective inhibitors have been reported for this kinase that would allow for investigation of the pharmacological role of PKMYT1 in the treatment of cancer. To address this need we conducted a focused screening effort that identified compound 1 as a weak PKMYT1 inhibitor. Introduction of a dimethylphenol dramatically increased potency on PKMYT1. These dimethylphenol analogs were found to exist as Type III atropisomers that could be separated and profiled as single enantiomers. Structure-based drug design aided by co-crystal structures of several analogs enabled optimization of cell-based potency and kinase selectivity. Parallel optimization of ADME properties led to the identification of potent and selective inhibitors of PKMYT1 with favorable pharmacokinetics. RP-6306 inhibits the phosphorylation of CDK1 Thr14 in vivo in tumor tissue and inhibits CCNE1-amplified tumor cell growth in several preclinical xenograft models. The first-in-class clinical candidate RP-6306 is currently being evaluated in Phase 1 clinical trials (NCT04855656) for treatment of various solid tumors.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.